Risk and management of patients with cancer and heart disease

Loreena Hill; Bruno Delgado; Ekaterini Lambrinou; Tara Mannion; Mark Harbinson; Claire McCune

doi:10.1007/s40119-023-00305-w

Risk and management of patients with cancer and heart disease

Loreena Hill^*, Bruno Delgado, Ekaterini Lambrinou, Tara Mannion, Mark Harbinson, Claire McCune

^*Autor correspondente para este trabalho

Resultado de pesquisa › revisão de pares

1 Citação (Scopus)

22 Transferências (Pure)

Resumo

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Idioma original	English
Páginas (de-até)	227-241
Número de páginas	15
Revista	Cardiology and Therapy
Volume	12
Número de emissão	2
DOIs	https://doi.org/10.1007/s40119-023-00305-w
Estado da publicação	Publicado - jun. 2023

ODS da ONU

Este resultado contribui para o(s) seguinte(s) Objetivo(s) de Desenvolvimento Sustentável

Acesso ao documento

10.1007/s40119-023-00305-wLicença:

63649744Final published version, 831 KBLicença:

http://hdl.handle.net/10400.14/40361Licença:

Outros arquivos e links

Link to publication in Scopus

CIIS: Centro de Investigação Interdisciplinar em Saúde
Barros, M. (PI), Rosa, N. (Investigador), Correia, M. J. (Investigador), Caldas, A. C. (Investigador), Amado, J. C. (Investigador), Figueiredo, A. S. (Investigador), Esteves, A. C. (Investigador), Mineiro, A. (Investigador), Abreu, A. M. (Investigador), Duarte, A. S. (Investigador), Almeida, S. F. (Investigador), Correia, A. (Investigador), Moura, A. (Investigador), Almeida, A. (Investigador), Araújo, B. (Investigador), Moura-Netto, C. (Investigador), Ferrito, C. (Investigador), Pais-Vieira, C. (Investigador), Festas, C. (Investigador), Marques-Vieira, C. (Investigador), Catré, D. (Investigador), Nunes, E. (Investigador), Jesus, É. (Investigador), Ribeiro, F. (Investigador), Rosário, F. (Investigador), Fernandes, G. (Investigador), Rato, J. R. (Bolseiro), Salgado, J. R. (Investigador), Neves-Amado, J. (Investigador), Amendoeira, J. (Investigador), Sá, L. (Investigador), Capelas, M. L. (Investigador), Vieira, M. M. (Investigador), Nunes, M. V. S. (Investigador), Cardoso, M. (Investigador), Veiga, N. J. (Investigador), Fonseca, P. (Investigador), Correia, P. N. (Investigador), Couto, P. (Investigador), Pontífice-Sousa, P. (Investigador), Ravasco, P. (Investigador), Carvalho, P. V. D. (Investigador), Alves, P. (Investigador), Melo, P. (Investigador), Silva, R. (Investigador), Canaipa, R. (Investigador), Noites, R. (Investigador), Rio, R. (Investigador), Almeida, S. (Investigador), Deodato, S. (Investigador), Caldeira, S. (Investigador), Silva, S. (Investigador), Borges, T. (Investigador), Silva, V. (Investigador), Charepe, Z. (Investigador), Rodrigues-Pires, F. (Voluntário), Veludo, F. (Investigador), Carmo, H. (Bolseiro), Romeiro, J. (Estudante), Melo, M. (Investigador), Braga, M. (Investigador), Amaral, T. (Investigador), Moreira, M. A. (Investigador), Guerra, N. (Estudante), Santos, P. (Investigador), Paço, S. (Estudante), Lynce, S. (Bolseiro), Miguel, S. (Estudante), Costa, T. (Investigador), Silva-Neves, V. (Investigador), Silva, A. (Investigador), Carvalho, A. R. (Investigador), Almeida, B. (Investigador), Figueiredo, C. (Investigador), Esteves, E. (Bolseiro), Araújo, F. M. (Investigador), Garcia, J. G. (Investigador), Santos, L. (Investigador), Santos, N. M. D. (Investigador), Lopes, P. (Investigador), Bornes, R. (Investigador), Silva, R. (Investigador), Costa, S. (Investigador), Silva, S. M. (Investigador), Marques, T. (Investigador), Almeida, A. (Investigador), Santos, M. (Bolseiro), Santos, P. (Investigador), Miguel, S. (Investigador), Mendes, K. (Investigador), Gomes, A. P. (Investigador), Henriques, J. M. P. (Investigador), Costa, H. A. F. P. (Investigador) & Ribeiro, P. (Investigador)
Fundação para a Ciência e a Tecnologia
1/01/20 → 31/12/24
Projeto

Citação

@article{6639996dc6164f7dbc18ddbb5a518370,

title = "Risk and management of patients with cancer and heart disease",

abstract = "Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient{\textquoteright}s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients{\textquoteright} functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.",

keywords = "Anthracycline, Cardiotoxicity, Heart failure, Risk stratification",

author = "Loreena Hill and Bruno Delgado and Ekaterini Lambrinou and Tara Mannion and Mark Harbinson and Claire McCune",

note = "Funding Information: Loreena Hill: honorarium from Vifor Pharma. Claire McCune: received funding from The Heart Trust Fund Registered Charity Number: NIC100399 (“Late Anthracycline Induced Cardiotoxicity—Childhood Cancer Survivors”; see https://clinicaltrials.gov/ct2/show/NCT04852965 ). Bruno Delgado, Ekaterini Lambrinou, Tara Mannion and Mark Harbinson have nothing to disclose. Funding Information: No funding or sponsorship was received for this study or the publication of this article. Loreena Hill: design, development, sourcing evidence, analysis, drafting and revision of the manuscript. Bruno Delgado: sourcing evidence, analysis, drafting and revision of the manuscript. Ekaterini Lambrinou: sourcing evidence, analysis, drafting and revision of the manuscript. Tara Mannion: sourcing evidence, analysis, drafting and revision of the manuscript. Mark Harbinson: drafting and revision of the manuscript. Claire McCune: development, sourcing evidence, analysis, drafting and revision of the manuscript. Loreena Hill: honorarium from Vifor Pharma. Claire McCune: received funding from The Heart Trust Fund Registered Charity Number: NIC100399 (“Late Anthracycline Induced Cardiotoxicity—Childhood Cancer Survivors”; see https://clinicaltrials.gov/ct2/show/NCT04852965 ). Bruno Delgado, Ekaterini Lambrinou, Tara Mannion and Mark Harbinson have nothing to disclose. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Funding Information: Mild asymptomatic CTRCD was defined as a new relative decline in global longitudinal strain (GLS) of more than 15% from baseline and or a new rise in biomarkers (with a preserved ejection fraction of 50% or more). Moderate asymptomatic CTRCD is defined as a reduction in ejection fraction of 10 percentage points or more to an ejection fraction of 40–49%. Alternatively, moderate asymptomatic CTRCD is diagnosed in patients with a reduction of less than 10 percentage points (to an ejection fraction of 40–49%) with a new decline in global longitudinal strain of more than 15% from baseline and/or a new rise in cardiac biomarkers. Severe asymptomatic CTRCD is defined as a new ejection fraction reduction to below 40%. The implementation of these definitions is supported by guidance from the European Haematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), the International Cardio-Oncology Society (IC-OS) and the task force on cardio-oncology of the European Society of Cardiology (ESC) []. Well-known cardiotoxic drugs include anthracyclines, as well as many targeted therapies such as small molecule tyrosine kinase inhibitors (sunitinib) and proteasome inhibitors (carfilzomib). The position statement from the Cardio-Oncology Study Group of the Heart Failure Association of the ESC in collaboration with the IC-OS provides a table outlining cancer therapy classes and their associated cardiovascular toxicities []. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jun,

doi = "10.1007/s40119-023-00305-w",

language = "English",

volume = "12",

pages = "227--241",

journal = "Cardiology and Therapy",

issn = "2193-8261",

publisher = "Adis",

number = "2",

}

TY - JOUR

T1 - Risk and management of patients with cancer and heart disease

AU - Hill, Loreena

AU - Delgado, Bruno

AU - Lambrinou, Ekaterini

AU - Mannion, Tara

AU - Harbinson, Mark

AU - McCune, Claire

N1 - Funding Information: Loreena Hill: honorarium from Vifor Pharma. Claire McCune: received funding from The Heart Trust Fund Registered Charity Number: NIC100399 (“Late Anthracycline Induced Cardiotoxicity—Childhood Cancer Survivors”; see https://clinicaltrials.gov/ct2/show/NCT04852965 ). Bruno Delgado, Ekaterini Lambrinou, Tara Mannion and Mark Harbinson have nothing to disclose. Funding Information: No funding or sponsorship was received for this study or the publication of this article. Loreena Hill: design, development, sourcing evidence, analysis, drafting and revision of the manuscript. Bruno Delgado: sourcing evidence, analysis, drafting and revision of the manuscript. Ekaterini Lambrinou: sourcing evidence, analysis, drafting and revision of the manuscript. Tara Mannion: sourcing evidence, analysis, drafting and revision of the manuscript. Mark Harbinson: drafting and revision of the manuscript. Claire McCune: development, sourcing evidence, analysis, drafting and revision of the manuscript. Loreena Hill: honorarium from Vifor Pharma. Claire McCune: received funding from The Heart Trust Fund Registered Charity Number: NIC100399 (“Late Anthracycline Induced Cardiotoxicity—Childhood Cancer Survivors”; see https://clinicaltrials.gov/ct2/show/NCT04852965 ). Bruno Delgado, Ekaterini Lambrinou, Tara Mannion and Mark Harbinson have nothing to disclose. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Funding Information: Mild asymptomatic CTRCD was defined as a new relative decline in global longitudinal strain (GLS) of more than 15% from baseline and or a new rise in biomarkers (with a preserved ejection fraction of 50% or more). Moderate asymptomatic CTRCD is defined as a reduction in ejection fraction of 10 percentage points or more to an ejection fraction of 40–49%. Alternatively, moderate asymptomatic CTRCD is diagnosed in patients with a reduction of less than 10 percentage points (to an ejection fraction of 40–49%) with a new decline in global longitudinal strain of more than 15% from baseline and/or a new rise in cardiac biomarkers. Severe asymptomatic CTRCD is defined as a new ejection fraction reduction to below 40%. The implementation of these definitions is supported by guidance from the European Haematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), the International Cardio-Oncology Society (IC-OS) and the task force on cardio-oncology of the European Society of Cardiology (ESC) []. Well-known cardiotoxic drugs include anthracyclines, as well as many targeted therapies such as small molecule tyrosine kinase inhibitors (sunitinib) and proteasome inhibitors (carfilzomib). The position statement from the Cardio-Oncology Study Group of the Heart Failure Association of the ESC in collaboration with the IC-OS provides a table outlining cancer therapy classes and their associated cardiovascular toxicities []. Publisher Copyright: © 2023, The Author(s).

PY - 2023/6

Y1 - 2023/6

N2 - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

AB - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

KW - Anthracycline

KW - Cardiotoxicity

KW - Heart failure

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85147769444&partnerID=8YFLogxK

U2 - 10.1007/s40119-023-00305-w

DO - 10.1007/s40119-023-00305-w

M3 - Review article

C2 - 36757637

AN - SCOPUS:85147769444

SN - 2193-8261

VL - 12

SP - 227

EP - 241

JO - Cardiology and Therapy

JF - Cardiology and Therapy

IS - 2

ER -

Risk and management of patients with cancer and heart disease

Resumo

ODS da ONU

Acesso ao documento

Outros arquivos e links

Impressão digital

Projetos

CIIS: Centro de Investigação Interdisciplinar em Saúde

Citação